IGC obtains final court approval of shareholder class action settlement; lawsuits dismissed

IGC Pharma, Inc.

Court granted final approval of settlement on April 13, 2022, dismissing Tchatchou and Harris-Carr consolidated class actions.
Settlement resolves all shareholder class action lawsuits pending against IGC and its officers.
Most settlement costs paid through company's insurance policy; terms previously disclosed in Form 10-Q filed Feb 10, 2022.
IGC continues Alzheimer's drug development with IGC-AD1, a THC-based investigational drug; Phase 2 trial planned.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.